Molecular methods for the detection of human papillomavirus infection: New insights into their role in diagnostics and epidemiological surveillance

Epidemiology Biostatistics and Public Health

Volumn 6, Issue 2, 2009, Pages 164-171

  Piana, Andrea ^a   Sotgiu, Giovanni ^a   Castiglia, Paolo ^a   Pischedda, Stefania ^a   Dettori, Marco ^a   Cocuzza, Clementina ^b   Muresu, Elena ^a   Maida, Alessandro ^a  

^a UNIVERSITY OF SASSARI   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

HPV infection; Molecular methods; Prevention of cervical cancer

Indexed keywords

EID: 78649307833     PISSN: None     EISSN: 22820930     Source Type: Journal    
DOI: 10.2427/5791     Document Type: Article

References (60)

1. Bernard H.U. The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses. J Clin Virol 2005;32:S1-S6.
2. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004;324(1):17-27.
3. Muñoz N, Castellsagué X, de González AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006;24S3:S1-S10.
4. Zheng ZM, Baker CC. Papillomavirus genome structure, expression, and post-transcriptional regulation. Front Biosci 2006;11:2286-302.
5. http://www.ncbi.nlm.nih.gov/Genbank/GenbankSearch.html [Accessed on 3-06-2009].
6. Howell-Jones R. Human papillomavirus vaccination: the United Kingdom s recommendation and update on European licensure and efficacy data. Eurosurveillance 2007;12(11):E071115.4.
7. Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 2007;7(1):11-22.
8. European guidelines for quality assurance in cervical cancer screening. II Edition. International Agency for research on cancer, 2008.
9. Schiller JT, Lowy DR. Prospects for cervical cancer prevention by human papillomavirus vaccination. Cancer Res 2006;66(21):10229-32.
10. Cuzick J, Sasieni P, Davies P, Adams J, Normand C, Frater A, van Ballegooijen M, & van den Acker. A systematic review of the role of human papillomavirus testing within a cervical screening programme. Health Technol Assess 1999; 3:1-196. Review.
11. Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994;169:235-40.
12. Tieben LM, ter Schegget J, Minnaar RP, Bouwes Bavinck J, Berkhout RJ, Vermeer BJ. Detection of cutaneous and genital HPV types in clinical samples by PCR using consensus primers. J Virol Methods 1993;42:265-79.
13. de Roda Husman AM, Walboomers JM, Hopman E, Bleker OP, Helmerhorst TM, Rozendaal L. HPV prevalence in cytomorphologically normal cervical scrapes of pregnant women as determined by PCR: the age-related pattern. J Med Virol 1995;46:97-102.
14. Jacobs MV, Snijders PJ, van den Brule AJ, Helmerhorst TJ, Meijer CJ, Walboomers JM. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 1997;35:791-5.
15. Jacobs MV, Snijders PJ, Voorhorst FJ, Dillner J, Forslund O, Johansson B et al. Reliable high risk HPV DNA testing by polymerase chain reaction: an intermethod and intramethod comparison. J Clin Pathol 1999; 52:498-503.
16. Elfgren K, Rylander E, Rådberg T, Strander B, Strand A, Paajanen K et al. Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence. Am J Obstet Gynecol 2005;193:650-7.
17. Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994;169:235-40.
18. Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlée F, Hildesheim A. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000;38:357-61.
19. Peyton CL, Schiffman MA, Lorincz AT, Hunt WC, Mielzynska I, Bratti C et al. Comparison of PCR and hybrid capture-based human papillomavirus detection system using multiple cervical specimen collection strategies. J Clin Microbiol 1998;36:3248-54.
20. Kornegay JR, Shepard AP, Hankins C, Franco EL, Lapointe N, Richardson H et al. Nonisotopic detection of human papillomavirus DNA in clinical specimens using a consensus PCR and a generic probe mix in an enzyme-linked immunosorbent assay format. J. Clin. Microbiol. 2001; 39: 3530-6.
21. Kleter B, van Doorn LJ, ter Schegget J, Schrauwen L, van Krimpen C, Burger MP. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am J Pathol 1998;153:1731-9.
22. Iftner T, Villa LL. Chapter 12: Human papillomavirus technologies. J Natl Cancer Inst Monogr 2003; 31:80-8.
23. Grce M, Husnjak K, Skerlev M, Lipozencić J, Pavelić K. Detection and typing of human papillomaviruses by means of polymerase chain reaction and fragment length polymorphism in male genital lesions. Anticancer Res. 2000;20:2097-102.
24. Kuypers J, Kuypers JM, Critchlow CW, Gravitt PE, Vernon DA, Sayer JB et al. Comparison of dot filter hybridization, southern transfer hybridization, and polymerase chain reaction amplification for diagnosis of anal human papillomavirus infection. J Clin Microbiol 1993;31:1003-6.
25. Arens M. Clinically relevant sequence-based genotyping of HBV, HCV, CMV, and HIV. J Clin Virol 2001;22:11-29.
26. Mo LZ, Monnier-Benoit S, Kantelip B, Petitjean A, Riethmuller D, Prétet JL et al. Comparison of AMPLICOR and Hybrid Capture II assays for high risk HPV detection in normal and abnormal liquid-based cytology: use of INNO-LiPA Genotyping assay to screen the discordant results. J Clin Virol 2008;41:104-10.
27. Schmitt M, Bravo IG, Snijders PJ, Gissmann L, Pawlita M, Waterboer T. Bead-based multiplex genotyping of human papillomaviruses. J Clin. Microbiol 2006; 44: 504-12.
28. Cavuslu S, Mant C, Starkey WG, Bible JM, Biswas C, Kell B et al. Analytic sensitivities of hybrid-capture, consensus and type-specific polymerase chain reactions for the detection of human papillomavirus type 16 DNA. J Med Virol 1996; 49: 319-24.
29. Lorincz AT. Methods of DNA hybridization and their clinical applicability to human papillomavirus detection. In: New developments in cervical cancer screening and prevention. Franco EL, Monsonego J, editors. Oxford: Blackwell Science, 1997: 325-37.
30. Bozzetti M, Nonnenmacher B, Mielzinska I, Villa L, Lorincz A, Breitenbach V. Comparison between Hybrid Capture II and polymerase chain reaction results among women at low-risk for cervical cancer. Ann Epidemiol 2000;10(7):466.
31. Lorincz AT. Hybrid Capture method for detection of human papillomavirus DNA in clinical specimens: a tool for clinical management of equivocal Pap smears and for population screening. J Obstet Gynaecol Res 1996;22(6):629-36.
32. Castle PE, Schiffman M, Burk RD, Wacholder S, Hildesheim A, Herrero R. Restricted cross-reactivity of Hybrid Capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol Biomarkers Prev 2002;11(11):1394-9.
33. Lorincz AT, Castle PE, Sherman ME, Scott DR, Glass AG, Wacholder S et al. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet 2002;360:228–9.
34. Moberg M, Gustavsson I, Gyllensten U. Real-time PCR-based system for simultaneous quantification of human papillomavirus types associated with high risk of cervical cancer. J Clin. Microbiol 2003; 41:3221-8.
35. Moberg M, Gustavsson I, Gyllenstein U. Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ. Int J Cancer 2004;112:854–9.
36. Moberg M, Gustavsson I, Wilander E, Gyllensten U. High viral loads of human papillomavirus predict risk of invasive cervical carcinoma. Br J Cancer 2005;92:891– 4.
37. Molden T, Nygård JF, Kraus I, Karlsen F, Nygård M, Skare GB et al. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow up of women with ASCUS or LSIL Pap smear. Int J Cancer 2005;114: 973-6.
38. Lie AK, Kristensen G. Human papillomavirus E6/E7 mRNA testing as a predictive marker for cervical carcinoma. Expert Rev Mol Diagn 2008;8(4):405-15.
39. Varnai AD, Bollmann M, Bankfalvi A, Speich N, Schmitt C, Griefingholt H et al. Predictive testing of early cervical precancer by detecting human papillomavirus E6/E7 mRNA in cervical cytologies up to high-grade squamous intraepithelial lesions: diagnostic and prognostic implications. Oncol Rep 2008;19(2):457-65.
40. Josefsson AM, Magnusson PK, Ylitalo N, Sorensen P, Qwarforth-Tubbin P, Andersen PK et al. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case–control study. Lancet 2000;355: 2189–93.
41. Kraus I, Molden T, Erno LE, Skomedal H, Karlsen F, Hagmar B. Human papillomavirus oncogenic expression in the dysplastic portio; an investigation of biopsies from 190 cervical cones. Br J Cancer. 2004;90:1407-13.
42. Lie AK, Isaksen CV, Skarsvag S, Haugen OA. Human papillomavirus (HPV) in high-grade cervical intraepithelial neoplasia (CIN) detected by morphology and polymerase chain reaction (PCR)—a cytohistologic correlation of 277 cases treated by laser conization. Cytopathology 1999;10:112-21.
43. Piana A, Broccolo F, Castiglia P, Mangioni C, Muresu E, Cocuzza C et al. Studio dell’associazione tra carica di HPV ad alto rischio e lesioni cervicali precancerose e cancerose. Atti: X Conferenza Nazionale di Sanità Pubblica. Pisa 14-16 ottobre 2007; 92: 271.
44. Broccolo F, Chiari S, Piana A, Castiglia P, Dell'Anna T, Garcia-Parra R et al. Prevalence and viral load of oncogenic human papillomavirus types associated with cervical carcinoma in a population of North Italy. J Med Virol 2009;81:278-87.
45. Castiglia P, Cocuzza C, Piana A, Mangioni C, Sotgiu G, Broccolo F et al. Comparazione tra la carica virale di HPV e la presenza dei trascritti oncogeni E6/E7 in campioni citologici cervicali. Atti: X Conferenza Nazionale di Sanità Pubblica. Pisa 14-16 ottobre 2007;93:271.
46. Berg A, Atkins D. Screening for cervical cancer. Recommendations and rationale. Guide to Clinical Preventive Services. 2nd Ed. US Preventive Services Task Force. Rockville, MD: Agency to Health Care Research and Quality 2004.
47. Wright Jr TC. Cervical cancer screening in the 21st century: is it time to retire the PAP smear? Clin Obstet Gynecol. 2007;50:313–23.
48. Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med. 2000;132:810–9.
49. Cohn DE, Herzog TJ. New innovations in cervical cancer screening. Clin Obstet Gynecol 2001;44:538–49.
50. Wright TC Jr. HPV DNA testing for cervical cancer screening. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95:S239-46. Review.
51. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119:1095−101.
52. Wright TC Jr, Schiffman M, Solomon D, Cox JT, Garcia F, Goldie S, Hatch K, Noller KL, Roach N, Runowicz C, Saslow D. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol. 2004; 103(2):304−9.
53. Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WG, Castle PE. Human Papillomavirus genotype distributions: implications for Vaccination and Cancer Screening in the United States. J Natl Cancer Inst. 2009; 101: 475–87.
54. Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst. 2008;100:308-20.
55. Broccolo F, Cocuzza CE. Automated extraction and quantitation of oncogenic HPV genotypes from cervical samples by real-time PCR-based system. J.Virol. Methods 2008;148: 48-57.
56. Daniel B, Rangarajan A, Mukherjee G, Vallikad E, Krishna S. The link between integration and expression of human papillomavirus type 16 genomes and cellular changes in the evolution of cervical intraepithelial neoplastic lesions. J Gen Virol. 1997;78:1095-101.
57. Castle PE, Wheeler CM, Solomon D, Schiffman M, Peyton CL. Interlaboratory reliability of Hybrid Capture 2. Am J Clin Pathol. 2004;122:238-45.
58. Schiffman MH, Kiviat NB, Burk RD, Shah KV, Daniel RW, Lewis R. Accuracy and interlaboratory reliability of human papillomavirus DNA testing by Hybrid Capture J Clin Microbiol. 1995;33:545-550.
59. http://www.gisci.it/[Accessed on 3-06-2009].
60. Molijin A, Kleter B, Quint W, van Doorn L. Molecular diagnosis of human Papillomavirus (HPV) infections. J Clin Virol. 2005;32 Suppl 1:S43.